Datopotamab (CDP7657, CAS 2267989-53-5) is a humanized monoclonal antibody that targets TROP2, a protein overexpressed in many epithelial cancers. By binding to TROP2, it helps stop cancer cell growth and boosts the immune system’s ability to destroy these cells.
Key Features:
- Target Specificity: Targets TROP2, found in many cancer types.
- Mechanism of Action: Blocks cancer cell growth and enhances immune destruction of cancer cells.
- Molecular Characteristics: Humanized IgG1 monoclonal antibody.
Datopotamab Applications:
- Cancer Therapy: Used to treat triple-negative breast cancer, non-small cell lung cancer, and other cancers.
- Antibody-Drug Conjugates (ADCs): Can form ADCs by linking to the DNA topoisomerase I inhibitor Deruxtecan for targeted drug delivery.
Datopotamab is given intravenously, often with other therapies. Common side effects include fatigue, nausea, and low blood counts. Ongoing clinical trials are studying its safety and effectiveness in different cancers.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
